Human Galatose-1-phosphate Uridylyltransferase (GALT); A Target Enabling Package
Creators
- 1. Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford
- 2. Department of Nutrition and Integrative Physiology, Pediatric Genetics, University of Utah
- 3. Department of Biochemistry, University of Utah
Description
This project describes a drug discovery plan for Classic Galactosemia, a rare disorder of galactose metabolism where there is currently no disease-transforming therapy. This TEP provides the protein reagents, biophysical assays, and structural information to facilitate two aspects of galactosemia research: (i) to understand the molecular basis of the disease due to defective GALT enzyme, and (ii) to provide chemical starting points to explore metabolic intervention of the upstream enzyme GALK1 aimed at mitigating the GALT defect (substrate reduction).
Files
GALT_TEP_datasheet_v1.pdf
Files
(8.6 MB)
Name | Size | Download all |
---|---|---|
md5:aedab959ebfffa256ec1f39361de8d38
|
8.6 MB | Preview Download |
Additional details
Related works
- Is part of
- https://www.thesgc.org/tep (URL)
Funding
- A UK Hub to Catalyse Open Target Discovery. 106169
- Wellcome Trust